Featured Research

from universities, journals, and other organizations

New drug treatment reduces chronic pain following shingles

Date:
February 4, 2014
Source:
Imperial College London
Summary:
A new drug treatment has been found to be effective against chronic pain caused by nerve damage, also known as neuropathic pain, in patients who have had shingles.

A new drug treatment has been found to be effective against chronic pain caused by nerve damage, also known as neuropathic pain, in patients who have had shingles.

The researchers hope that the drug might also be effective against other causes of chronic neuropathic pain, such as diabetes, HIV, nerve injury and cancer chemotherapy, as it targets a mechanism that is not targeted by any existing therapies and has fewer side effects.

Drugs available now have limited success at treating neuropathic pain and often have unpleasant or disabling side effects.

It is estimated that around 190,000 people in the UK get shingles every year, most of them aged over 50. It is caused when a dormant viral infection of a nerve is reactivated, resulting in a painful rash. In most cases, the shingles rash lasts a few weeks, but in some cases the permanent nerve damage caused by the virus results in a chronic neuropathic pain called post-herpetic neuralgia. Around one in 10 people with shingles experiences post-herpetic neuralgia and, once established, it usually causes life-long suffering.

In a study involving 183 patients with post-herpetic neuralgia in six countries, the new drug EMA401 was found to reduce pain and did not cause any serious side effects. The findings are published in The Lancet.

Lead author Professor Andrew Rice, from the Department of Surgery and Cancer at Imperial College London, said: "Conventional painkillers don't tend to help people with severe chronic neuropathic pain and most available treatments have modest efficacy and/or are limited by side effects. We are therefore keen to find new ways of providing these people with some relief.

"A positive trial like this in such a challenging condition as post-herpetic neuralgia, for a drug that acts in a new way, is unusual and very exciting. We hope that the new drug will ultimately offer hope for patients who aren't helped by current treatments."

The study, a phase 2 trial, compared EMA401 with a placebo, with participants taking two pills a day for four weeks. Fifty-eight per cent of participants taking the drug found it effective, reducing pain by at least 30 per cent.

Spinifex Pharmaceuticals, which owns the drug, now plans to conduct a larger trial, possibly testing higher doses of the drug for longer periods of time.

"We are looking forward to seeing how EMA401 performs in a larger trial in people with post-herpetic neuralgia, where we will explore higher doses, and in trials where we will analyse its efficacy in other chronic pain conditions. Identifying the characteristics of the patients who do get good pain relief from EMA401 will also be an important avenue for research," added Professor Rice.

Tom McCarthy, CEO of Spinifex Pharmaceuticals, said: "There is a clear need for new treatments that bring patients pain relief with fewer side effects. In addition to post-herpetic neuralgia, we see broad potential for EMA401 to treat a range of chronic painful conditions such as pain due to osteoarthritis and diabetes. We look forward to delivering on the further development of EMA401."


Story Source:

The above story is based on materials provided by Imperial College London. Note: Materials may be edited for content and length.


Journal Reference:

  1. Andrew S C Rice, Robert H Dworkin, Tom D McCarthy, Praveen Anand, Chas Bountra, Philip I McCloud, Julie Hill, Gary Cutter, Geoff Kitson, Nuket Desem, Milton Raff. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. The Lancet, 2014; DOI: 10.1016/S0140-6736(13)62337-5

Cite This Page:

Imperial College London. "New drug treatment reduces chronic pain following shingles." ScienceDaily. ScienceDaily, 4 February 2014. <www.sciencedaily.com/releases/2014/02/140204220559.htm>.
Imperial College London. (2014, February 4). New drug treatment reduces chronic pain following shingles. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2014/02/140204220559.htm
Imperial College London. "New drug treatment reduces chronic pain following shingles." ScienceDaily. www.sciencedaily.com/releases/2014/02/140204220559.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) — A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) — The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) — The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) — Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:  

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile iPhone Android Web
          Follow Facebook Twitter Google+
          Subscribe RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins